Advances in targeting cyclic nucleotide phosphodiesterases

DH Maurice, H Ke, F Ahmad, Y Wang… - Nature reviews Drug …, 2014 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and
cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides …

Clinical and molecular genetics of the phosphodiesterases (PDEs)

MF Azevedo, FR Faucz, E Bimpaki, A Horvath… - Endocrine …, 2014 - academic.oup.com
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …

A SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial function

D Ryu, YS Jo, GL Sasso, S Stein, H Zhang, A Perino… - Cell metabolism, 2014 - cell.com
Mitochondrial activity is controlled by proteins encoded by both nuclear and mitochondrial
DNA. Here, we identify Sirt7 as a crucial regulator of mitochondrial homeostasis. Sirt7 …

Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth

M Li, V Sala, MC De Santis, J Cimino, P Cappello… - Circulation, 2018 - Am Heart Assoc
Background: Anthracyclines, such as doxorubicin (DOX), are potent anticancer agents for
the treatment of solid tumors and hematologic malignancies. However, their clinical use is …

Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure

R Kamel, J Leroy, G Vandecasteele… - Nature Reviews …, 2023 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) modulate the neurohormonal regulation of
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …

The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitors

D Paes, M Schepers, B Rombaut… - Pharmacological …, 2021 - Elsevier
Abstract The phosphodiesterase 4 (PDE4) enzyme family plays a pivotal role in regulating
levels of the second messenger cAMP. Consequently, PDE4 inhibitors have been …

Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases

F Vinchi, L De Franceschi, A Ghigo, T Townes… - Circulation, 2013 - Am Heart Assoc
Background—Hemolytic diseases are characterized by enhanced intravascular hemolysis
resulting in heme-catalyzed reactive oxygen species generation, which leads to endothelial …

PI3K and calcium signaling in cardiovascular disease

A Ghigo, M Laffargue, M Li, E Hirsch - Circulation research, 2017 - Am Heart Assoc
Receptor signaling relays on intracellular events amplified by secondary and tertiary
messenger molecules. In cardiomyocytes and smooth muscle cells, cyclic AMP (cAMP) and …

Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets

F Ahmad, T Murata, K Shimizu, E Degerman… - Oral …, 2015 - Wiley Online Library
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their …

Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction

Q Wang, Y Liu, Q Fu, B Xu, Y Zhang, S Kim, R Tan… - Circulation, 2017 - Am Heart Assoc
Background: Type 2 diabetes mellitus (DM) and obesity independently increase the risk of
heart failure by incompletely understood mechanisms. We propose that hyperinsulinemia …